Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Sun will turn Ranbaxy profitable; stock fall brief: Angel

    • Cipla Q4 profit seen up 29% at Rs 335.8 cr: Poll

    • Mixed Q3 nos for pharma so far: Here's what you should buy

    • Cipla Q3 profit may climb 27% to Rs 361 cr: CNBC-TV18 Poll

    • Cipla Q2 disappoints; net profit down 16.6%

    • US core business continues to be a drag for Ranbaxy: CIMB

    • Religare downgrades Cipla on cost overruns

    • FY15 capex Rs 400 cr, aiming for 20% EBITDA growth: Cipla

    • Cipla Q3 PAT may rise 6.1% to Rs 360 cr: CNBC-TV18 poll

    • Pharma companies revenues to rise 12% in Q3: Anand Rathi

    • H1 inline; Cipla Medpro fully integrated: Cipla MD

    • Cipla Q2 PAT may dip 27.3% at Rs 363.3 cr: ICICIdirect

    • Experts laud Cipla Q1 results; doubt Sun Pharma guidance

      Vivek Kumar Pharma Analyst SBI Cap Securities and Praful Bohra Senior Research Analyst Pharma, Nirmal Bang Institutional Equities share their views on the results of both the companies.

    • Cipla Q1 PAT may dip 15% at Rs 340 cr: Nirmal Bang

      Nirmal Bang expects Cipla to report a 26.9 percent growth quarter-on-quarter (fall of 15.3 percent year-on-year) in net profit at Rs 339.6 crore.

    • Cipla Q1 net seen down 18% at Rs 328 cr: P Lilladher

      Prabhudas Lilladher expects Cipla to report a 22.7 percent growth quarter-on-quarter (fall of 18.1 percent year-on-year) in net profit at Rs 328.2 crore.

    • Cipla Q1 PAT seen up 12.2% at Rs 343 cr: Motilal Oswal

      Motilal Oswal expects Cipla to report a 28.2 percent growth quarter-on-quarter (rise of 12.2 percent year-on-year) in net profit at Rs 342.9 crore.

    • Cipla Q1: Analysts see 17% drop in profit at Rs 332 cr

      Cipla's earning before interest, tax, depreciation & amortisation (EBITDA) is seen going down by 9 percent Y-o-Y to Rs 491 crore due to higher research & development cost and operating profit margin may drop 450 bps Y-o-Y to 23 percent for the quarter ended June 2013.

    • Cipla eyes strong intl growth; emerging mkts in focus

      Cipla aims to focus more on international business and will strengthen its presense in US, Europe. The company is also closely eyeing emerging markets

    • Pharma cos likely to post 21% EBITDA growth in Q4: MOST

      Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

    • Cipla Q3: Analysts expect Q3 profit to grow 38% at Rs 372cr

      Healthcare firm Cipla is set to announce its results for the third quarter of financial year 2012-13 on Wednesday. Analysts on an average expect the company to report good numbers year-on-year due to overall operational improvement.

    • See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

      Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.

    • Cipla Q2 net sales rises 33% to Rs 2,146 cr

      Pharmaceutical firm Cipla's net sales increased 33 percent YoY to Rs 2,146 crore in the July-September quarter of 2012, out of which 44 percent contribution came from local business and 56 percent from international, Hamied says.

    • Aim to see turnover of USD 5 bn by 2020: Cipla Chairman

      Cipla reported a better-than-expected second quarter earnings. In an interview to CNBC-TV18, Chairman of the company YK Hamied said that the pharma major is expecting to achieve a turnover of USD 5 billion by the year 2020.

    • Cipla Q2 revenues seen up 26% to Rs 2,030 cr

      Drug producer Cipla's revenues are seen going up by 26 percent to Rs 2,030 crore from Rs 1,615 crore during the same period.

    • Cipla Q2 PAT seen up 37.5% to Rs 361 cr

      Drug producer Cipla's profit after tax is expected to go up by 37.5 percent year-on-year to Rs 361 crore in the quarter ended September 2012.

    Advisory Alert:

    It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347